医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Shofu Dental Brasil, Super-Bond™ Dental Adhesive to Launch in Brazil

2023年04月26日 PM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

SHOFU INC. (Tokyo: 7979; President & COO: TAKAMI Tetsuo), SUN MEDICAL CO., LTD. (Head Office: Moriyama, Shiga; President & CEO: NAKAJIMA Yoshiyuki) and Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that Shofu Dental Brasil Comercio de Produtos Odontologicos Ltda. (Shofu Brasil; Head Office: Sao Paulo, Brazil; President: HARASHIMA Tomomi), a sales subsidiary of SHOFU, will launch Brazilian sales of SUN MEDICAL’s Super-Bond™ dental adhesive in June 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005025/en/

Super-Bond™ (Photo: Business Wire)

Super-Bond™ (Photo: Business Wire)

Employing 4-methacryloxyethyl trimellitate anhydride (4-META) as a dispersion-aiding monomer and tributylborane (TBB) as a polymerization initiator, Super-Bond™ is an acrylic resin cement made for use as a dental adhesive. It is referred to in academic literature as a 4-META/MMA-TBB resin. SUN MEDICAL began producing and selling the product in 1982, and since sales first began in Japan, the material has become a favorite among dentists due to its excellent adhesive properties and ample track record of effectiveness. Super-Bond™ finds use in a wide range of applications, including stabilizing mobile teeth, forming direct resin-bonded bridges, and enabling the adhesion of brackets and ceramic prostheses. The material enjoys widespread use in clinical settings around the world, with exports already going out to the U.S., Europe, China and South Korea.

Super-Bond™ is made up of a polymerization initiator, a liquid and a polymer powder, and exhibits excellent adhesion to tooth material (enamel/dentin), dental alloys and ceramics alike. The product’s mechanism sees Catalyst V, which has TBB as its main component, react with water and oxygen to serve as a polymerization initiator. Super-Bond™ is especially notable for its adhesion to tooth material, which is difficult to keep completely dry: since hardening begins at the adhesive interface, the product is able to exhibit better adhesive strength and adhesive durability here than conventional resin cements.

Super-Bond™ recently received pharmaceutical approval in Brazil, where the dentistry market looks set for growth going forward. This then prompted the decision to begin sales in this market, helping those in the country to keep their natural teeth for longer. Starting with an exhibition at CIOCE 2023 – an international dentistry conference set to be held in Fortaleza over May 6–9, 2023 – efforts will be made to gradually introduce the product across the country via KOL marketing at seminars and other such venues.

Comment from President HARASHIMA Tomomi of Shofu Brasil, which will sell the material:
We are honored to announce the Brazilian launch of Super-Bond™, which has been held in high regard among dentists for some 40 years. Based on its excellent clinical results so far, we believe that sales of the product will aid dental treatment in Brazil, where minimally invasive surgery has been on the rise.

Overview of CIOCE
An international dentistry conference held in Brazil. This year, the event is set to be hosted in Fortaleza over May 6–9.

CIOCE 2023: https://cioce.com.br/

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005025/en/

CONTACT

For inquiries relating to this news release, please contact:

SHOFU INC. General Affairs

TEL: +81-75-561-1914

Email: pr@shofu.co.jp

SUN MEDICAL CO., LTD. General Affairs Department

TEL: +81-77-582-9981

Email: pr@sunmedical.co.jp

Mitsui Chemicals, Inc. Corporate Communications Division

TEL: +81-3-6253-2100

Inquiry form: https://form.mitsuichemicals.com/corporate/cc_pr_csr_en

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024